logo-loader

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian cancer

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer.

The CEO said the first part of the study has shown some very promising signals, and the data from Part B will significantly enhance understanding of the drug.

The company will be presenting data to the upcoming ESMO conference in September.

Kazia is also making news with its treatment strategies for different types of brain cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Archer Materials hits another milestone with Quantum devices successfully...

Archer Materials (ASX: AXE) Chief Executive Officer DR Mohammad Choucair joined Steve Darling from Proactive to bring news the company has built Qubit control devices for quantum control measurements to characterise Archer’s unique 12CQ qubit processor chip components. Choucair talks about...

4 hours, 10 minutes ago

2 min read